Traws Pharma (TRAW) Research & Development (2012 - 2026)
Traws Pharma (TRAW) posted quarterly Research & Development of $4.9 million for Q1 2026, up 96.01% year-over-year from $2.5 million in Q1 2025, and down 2.44% quarter-over-quarter from $5.0 million in Q4 2025.
Traws Pharma (TRAW) Research & Development (2012 - 2026) Analysis & Trends
Traws Pharma (TRAW) has reported Research & Development for 15 consecutive years, with $4.9 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Research & Development rose 96.01% year-over-year to $4.9 million; the TTM figure through Mar 2026 stood at $14.5 million (up 8.24% YoY), while the FY2025 annual figure was $12.1 million, down 5.48% from the prior year.
- Research & Development fell to $4.9 million in Q1 2026 per TRAW's latest filing, from $5.0 million in the prior quarter.
- Across five years, Research & Development topped out at $5.1 million in Q3 2024 and bottomed at $1.9 million in Q4 2024.
- Historically, Research & Development has averaged $3.1 million across 5 years, with a median of $2.5 million in 2023.
- On a YoY basis, Research & Development climbed as much as 170.99% in 2025 and fell as far as 54.8% in 2025.
- Traws Pharma's Research & Development stood at $3.8 million in 2022, then sank by 35.49% to $2.4 million in 2023, then declined by 23.66% to $1.9 million in 2024, then soared by 170.99% to $5.0 million in 2025, then decreased by 2.44% to $4.9 million in 2026.
- Business Quant data shows TRAW's Research & Development at $4.9 million in Q1 2026, $5.0 million in Q4 2025, and $2.3 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | R&D (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 993.80 Mn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 1.63 Bn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | 1.37 Bn |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | 651.00 Mn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 612.28 Mn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 413.13 Mn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | 210.03 Mn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 97.90 Mn |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | -588.31 Mn |
| 10 | Traws Pharma | 5.60 Mn | 588,417.40 | - | 1.10 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 4.91 Mn |
| Dec 31, 2025 | 5.04 Mn |
| Sep 30, 2025 | 2.31 Mn |
| Jun 30, 2025 | 2.29 Mn |
| Mar 31, 2025 | 2.51 Mn |
| Dec 31, 2024 | 1.86 Mn |
| Sep 30, 2024 | 5.11 Mn |
| Jun 30, 2024 | 3.96 Mn |
| Mar 31, 2024 | 1.91 Mn |
| Dec 31, 2023 | 2.43 Mn |
| Sep 30, 2023 | 2.46 Mn |
| Jun 30, 2023 | 2.46 Mn |
| Mar 31, 2023 | 4.08 Mn |
| Dec 31, 2022 | 3.77 Mn |
| Sep 30, 2022 | 3.59 Mn |
| Jun 30, 2022 | 2.04 Mn |
| Mar 31, 2022 | 2.00 Mn |
| Dec 31, 2021 | 1.75 Mn |
| Sep 30, 2021 | 1.76 Mn |
| Jun 30, 2021 | 1.85 Mn |